European Society of Cardiology (ESC)

Limb Event Risk and the Benefit of Ticagrelor in Patients With and Without Peripheral Artery Disease: Insights From the THEMIS Trial

Ticagrelor With AspIrin or ALone In HiGH-Risk PaTients With Diabetes Mellitus After Coronary Intervention: The TWILIGHT-CKD Study

The Effect of One Year Post-Operative Ticagrelor in Addition to Aspirin on Saphenous Vein Graft Patency in Patients Undergoing CABG — A Randomized, Multicenter, Double-blind, Placebo-Controlled Trial [content at timestamp: 1:03:00]

Prevalence of Type 2 Diabetes With Stable Coronary Artery Disease but Without Prior Myocardial Infarction or Stroke and THEMIS-Like Patients From the SNDS French Nationwide Claims Database

Real World Risk of Major Outcomes For Type 2 Diabetes With Stable Coronary Artery Disease Without Prior Myocardial Infarction or Stroke and THEMIS-Like Patients Using the SNDS French Nationwide Claims Database

Orodispersible Ticagrelor Use in Acute Coronary Syndrome Patients: The Ticagrelor Administered as Standard Tablet or OrodispersiblE FoRmulation (TASTER) Study

Cost-effectiveness of Ticagrelor in Patients With Type 2 Diabetes and Coronary Artery Disease With a History of PCI: An Economic Evaluation of THEMIS-PCI Using a Swedish Healthcare Perspective

Administration of a Soluble ADPase, AZD3366, on Top of Ticagrelor Confers Additional Cardioprotective Benefits to that of Ticagrelor Alone

DAPA-CKD - Dapagliflozin in Patients with Chronic Kidney Disease [content at timestamp: 2:55:40]

Efficacy and Safety of Dapagliflozin According to Baseline Blood Pressure — Observations From DECLARE-TIMI 58 Trial

Dapagliflozin Reduces the Risk of Hyperkalaemia in Patients With Heart Failure and Reduced Ejection Fraction: A Secondary Analysis DAPA-HF

Natriuretic Effect of 2 Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function: Results of the DAPASALT Trial

The Effect of Dapagliflozin in Patients With HFrEF and COPD: A Post-Hoc Analysis of DAPA-HF

The Effect of Dapagliflozin Across the Spectrum of Baseline Risk: A Post-Hoc Analysis of DAPA-HF

The Relationship Between Duration of Heart Failure, Serum Potassium Concentration and Adverse Clinical Outcomes

Assessing the Relationship Between Serum Potassium Variability and the Risk of Hyperkalaemia and Adverse Clinical Outcomes

Estimating the Burden of Hyperkalaemia in the UK in High-risk Patient Populations

An Epigenetic Circuit Linking Oxidative Stress DNA Hydroxymethylation in Heart Failure

Lifetime Risk of Cardiovascular-Renal Disease in Type 2 Diabetes: A Population-Based Study in 473,399 Individuals

Long Non-Coding RNA VENTHEART Is Required for Cardiomyocyte Specification and Function

Resting Coronary Blood Flow Velocity Profile Predicts Coronary Flow Reserve in HFpEF